Literature DB >> 32173463

NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis.

Lise Lurienne1, Julie Cervesi1, Lola Duhalde2, Jean de Gunzburg1, Antoine Andremont3, Gérard Zalcman4, Renaud Buffet1, Pierre-Alain Bandinelli5.   

Abstract

Immune checkpoint inhibitors (ICIs) have dramatically improved patient outcomes in a variety of tumor types, but with variable efficacy. Recent research has suggested that antibiotic-induced disruption of the microbiota may impact ICI efficacy. We performed a systematic review and meta-analysis of studies that assessed the impact of antibiotic use on the survival of patients diagnosed with NSCLC and treated with ICI. We systematically searched Medline, the Cochrane Library, and major oncology conferences proceedings. Eligible studies mentioned hazard ratio or Kaplan-Meier curves for progression-free survival (PFS) or overall survival (OS) based on antibiotic exposure before or during ICI treatment. We identified 23 eligible studies. The impact of antibiotics was then evaluated in 2208 patients for PFS and 5560 for OS. For both PFS and OS meta-analyses, the between-study heterogeneity was high (Higgins and Thompson I2 of 69% and 80%, respectively). The pooled hazard ratio was 1.47 (95% confidence interval [CI]: 1.13-1.90) for PFS and 1.69 (95% CI: 1.25-2.29) for OS revealing a significantly reduced survival in patients with NSCLC exposed to antibiotics. The median OS was reduced on average by 6.7 months (95% CI: 5.1-8.4) in the patients exposed to antibiotics. The effect seems to depend on the time window of exposure with stronger effects reported when the patients took antibiotics [-60 days; +60 days] around ICI initiation. In patients with NSCLC, the findings of the meta-analysis indicate that antibiotic use before or during treatment with ICI leads to a median OS decreased by more than 6 months. Specifically, exposure shortly before or after ICI initiation seems to be particularly detrimental, whereas antibiotic use later during disease course does not seem to alter survival. Because PFS and OS were difficult to compare between studies owing to heterogeneity and the multiple confounding factors identified, further studies are needed to strengthen the understanding of this phenomenon.
Copyright © 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibiotics; Immune checkpoint inhibitors; Meta-analysis; Microbiota; Non–small cell lung cancer

Mesh:

Substances:

Year:  2020        PMID: 32173463     DOI: 10.1016/j.jtho.2020.03.002

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  24 in total

1.  Different classes of antibiotics exhibit disparate negative impacts on the therapeutic efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients.

Authors:  Hui Qiu; Qing-Gong Ma; Xue-Ting Chen; Xin Wen; Nie Zhang; Wan-Ming Liu; Ting-Ting Wang; Long-Zhen Zhang
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

2.  Tumor microbiome links cellular programs and immunity in pancreatic cancer.

Authors:  Bassel Ghaddar; Antara Biswas; Chris Harris; M Bishr Omary; Darren R Carpizo; Martin J Blaser; Subhajyoti De
Journal:  Cancer Cell       Date:  2022-10-10       Impact factor: 38.585

Review 3.  Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy.

Authors:  Roseanna C Wheatley; Elaine Kilgour; Timothy Jacobs; Angela Lamarca; Richard A Hubner; Juan W Valle; Mairéad G McNamara
Journal:  Br J Cancer       Date:  2021-10-18       Impact factor: 9.075

Review 4.  How Could Antibiotics, Probiotics, and Corticoids Modify Microbiota and Its Influence in Cancer Immune Checkpoint Inhibitors: A Review.

Authors:  Mara Cruellas; Alfonso Yubero; María Zapata; Eva M Galvez; Marta Gascón; Dolores Isla; Rodrigo Lastra; Luis Martínez-Lostao; Maitane Ocariz; Julián Pardo; Ariel Ramírez; Andrea Sesma; Irene Torres-Ramón; José Ramón Paño
Journal:  Infect Immun       Date:  2021-08-16       Impact factor: 3.441

Review 5.  Influence of immunomodulatory drugs on the gut microbiota.

Authors:  Inessa Cohen; William E Ruff; Erin E Longbrake
Journal:  Transl Res       Date:  2021-01-27       Impact factor: 10.171

Review 6.  Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors.

Authors:  Wenhui Liu; Ying Wang; Jianquan Luo; Mouze Liu; Zhiying Luo
Journal:  Front Immunol       Date:  2021-02-02       Impact factor: 7.561

Review 7.  Immunomodulation by the Commensal Microbiome During Immune-Targeted Interventions: Focus on Cancer Immune Checkpoint Inhibitor Therapy and Vaccination.

Authors:  Abigail L Reens; Damien J Cabral; Xue Liang; James E Norton; Alex G Therien; Daria J Hazuda; Gokul Swaminathan
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

8.  Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer.

Authors:  Andrew F Nyein; Shahla Bari; Stephanie Hogue; Yayi Zhao; Bradley Maller; Sybil Sha; Maria F Gomez; Dana E Rollison; Lary A Robinson
Journal:  BMC Cancer       Date:  2022-01-24       Impact factor: 4.430

Review 9.  Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges.

Authors:  Fang Yang; Jacqueline F Wang; Yucai Wang; Baorui Liu; Julian R Molina
Journal:  Cancers (Basel)       Date:  2021-12-27       Impact factor: 6.639

10.  Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer.

Authors:  Bao-Dong Qin; Xiao-Dong Jiao; Xin-Cheng Zhou; Bin Shi; Jian Wang; Ke Liu; Ying Wu; Yan Ling; Yuan-Sheng Zang
Journal:  Oncoimmunology       Date:  2021-07-21       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.